Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Autoimmune Disorders

  Free Subscription


25.03.2019

1 Brain
1 J Autoimmun
3 J Immunol
2 J Neuroimmunol
2 J Neurol
1 J Pediatr
1 Kidney Int
2 Mult Scler
3 Neurology
2 PLoS One
1 Proc Natl Acad Sci U S A
2 Thyroid


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Brain

  1. KINGWELL E, Leray E, Zhu F, Petkau J, et al
    Multiple sclerosis: effect of beta interferon treatment on survival.
    Brain. 2019 Mar 18. pii: 5382233. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Autoimmun

  2. ERDEI E, Shuey C, Miller C, Pacheco B, et al
    Elevated autoimmunity in residents living near abandoned uranium mine sites on the Navajo Nation.
    J Autoimmun. 2019 Mar 13. pii: S0896-8411(18)30700.
    PubMed     Text format     Abstract available


    J Immunol

  3. JOAO C, Negi VS, Kazatchkine MD, Bayry J, et al
    Passive Serum Therapy to Immunomodulation by IVIG: A Fascinating Journey of Antibodies.
    J Immunol. 2018;200:1957-1963.
    PubMed     Text format     Abstract available

  4. NYHOFF LE, Clark ES, Barron BL, Bonami RH, et al
    Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages.
    J Immunol. 2018;200:2352-2361.
    PubMed     Text format     Abstract available

  5. PODOJIL JR, Hecht I, Chiang MY, Vaknin I, et al
    ILDR2-Fc Is a Novel Regulator of Immune Homeostasis and Inducer of Antigen-Specific Immune Tolerance.
    J Immunol. 2018;200:2013-2024.
    PubMed     Text format     Abstract available


    J Neuroimmunol

  6. ANNUNZIATA P, Masi G, Cioni C
    Association of circulating anti-CD64 IgM levels with favourable long-term clinical outcomes in multiple sclerosis patients.
    J Neuroimmunol. 2019;330:130-135.
    PubMed     Text format     Abstract available

  7. HILLIS JM, Mateen FJ
    Neuromyelitis optica after splenectomy: A secondary autoimmune phenomenon.
    J Neuroimmunol. 2019;330:152-154.
    PubMed     Text format     Abstract available


    J Neurol

  8. BLOCK VJ, Lizee A, Crabtree-Hartman E, Bevan CJ, et al
    Continuous daily assessment of multiple sclerosis disability using remote step count monitoring.
    J Neurol. 2016.
    PubMed     Text format     Abstract available

  9. GAO J, Jones J, Damato EM, Coles A, et al
    Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis.
    J Neurol. 2019 Mar 20. pii: 10.1007/s00415-019-09288.
    PubMed     Text format    


    J Pediatr

  10. STEPHENS S, Shams S, Lee J, Grover SA, et al
    Benefits of Physical Activity for Depression and Fatigue in Multiple Sclerosis: A Longitudinal Analysis.
    J Pediatr. 2019 Mar 13. pii: S0022-3476(19)30128.
    PubMed     Text format     Abstract available


    Kidney Int

  11. VAN DE LOGT AE, Dahan K, Ronco P, Wetzels J, et al
    The authors reply.
    Kidney Int. 2018;94:830.
    PubMed     Text format    


    Mult Scler

  12. D'AMBROSIO A, Valsasina P, Gallo A, De Stefano N, et al
    Reduced dynamics of functional connectivity and cognitive impairment in multiple sclerosis.
    Mult Scler. 2019 Mar 19:1352458519837707. doi: 10.1177/1352458519837707.
    PubMed     Text format     Abstract available

  13. RUSSO CV, Sacca F, Paternoster M, Buonomo AR, et al
    Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2019 Mar 18:1352458518813110. doi: 10.1177/1352458518813110.
    PubMed     Text format    


    Neurology

  14. GORIS A, Dubois B
    Leveraging human genetics to inform intervention strategies for multiple sclerosis.
    Neurology. 2019 Mar 20. pii: WNL.0000000000007298.
    PubMed     Text format    

  15. THOMSON A, Horne R, Chung C, Marta M, et al
    Visibility and representation of women in multiple sclerosis research.
    Neurology. 2019 Mar 20. pii: WNL.0000000000007276.
    PubMed     Text format     Abstract available

  16. HARROUD A, Morris JA, Forgetta V, Mitchell R, et al
    Effect of age at puberty on risk of multiple sclerosis: A mendelian randomization study.
    Neurology. 2019 Mar 20. pii: WNL.0000000000007325.
    PubMed     Text format     Abstract available


    PLoS One

  17. SCHEIDLER AM, Kinnett-Hopkins D, Learmonth YC, Motl R, et al
    Targeted ballet program mitigates ataxia and improves balance in females with mild-to-moderate multiple sclerosis.
    PLoS One. 2018;13:e0205382.
    PubMed     Text format     Abstract available

  18. LASO-GARCIA F, Ramos-Cejudo J, Carrillo-Salinas FJ, Otero-Ortega L, et al
    Therapeutic potential of extracellular vesicles derived from human mesenchymal stem cells in a model of progressive multiple sclerosis.
    PLoS One. 2018;13:e0202590.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  19. GOBEL K, Asaridou CM, Merker M, Eichler S, et al
    Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release.
    Proc Natl Acad Sci U S A. 2019;116:271-276.
    PubMed     Text format     Abstract available


    Thyroid

  20. MALMSTROEM S, Grove-Laugesen D, Riis AL, Bruun BJ, et al
    Muscle performance and postural stability are reduced in patients with newly diagnosed Graves' disease.
    Thyroid. 2019 Mar 18. doi: 10.1089/thy.2018.0318.
    PubMed     Text format     Abstract available

  21. DRAMAN MS, Morris D, Evans S, Haridas A, et al
    PROSTAGLANDIN F2-ALPHA EYE DROPS (BIMATOPROST) IN GRAVES' ORBITOPATHY: A RANDOMISED CONTROLLED DOUBLE MASKED CROSSOVER TRIAL (BIMA TRIAL).
    Thyroid. 2019 Mar 18. doi: 10.1089/thy.2018.0506.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: